论文部分内容阅读
目的:观察苦参素注射液联合胸腺肽а1b治疗慢性乙型肝炎(CHB)的疗效。方法:选择慢性乙型肝炎患者168例,随机分成治疗组84例,对照组84例,治疗组运用苦参素注射液联合胸腺肽а1b治疗,对照组单用重组人干扰素а2b注射液治疗,疗程均为6个月,观察两组患者治疗前后肝功能及乙肝病毒标志物的变化情况。结果:苦参素注射液联合胸腺肽а1治疗CHB,降ALT有效率为92.8%,HBV-DNA阴转率为30.9%,HBeAg阴转率为38.0%,与干扰素治疗CHB疗效相近,且治疗过程中末发现明显不良反应。提示:苦参素注射液联合胸腺肽а1治疗CHB安全有效,与单用干扰素治疗CHB疗效相近。
Objective: To observe the efficacy of oxymatrine injection combined with thymosin а1b in the treatment of chronic hepatitis B (CHB). Methods: A total of 168 patients with chronic hepatitis B were randomly divided into treatment group (n = 84) and control group (n = 84). The treatment group was treated with oxymatrine injection combined with thymosin а1b. The control group received recombinant human interferon а2b injection. All were 6 months. The changes of liver function and HBV markers before and after treatment in both groups were observed. Results: Oxymatrine injection combined with thymosin а1 treatment of CHB, ALT reduction was 92.8%, HBV-DNA negative conversion rate was 30.9%, HBeAg negative conversion rate was 38.0%, and interferon treatment of CHB similar efficacy and course of treatment In the end found significant adverse reactions. Tip: Oxymatrine injection combined thymosin а1 treatment of CHB safe and effective, and interferon alone treatment of CHB effect is similar.